• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by 180 Life Sciences Corp.

    1/28/25 6:00:58 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email
    S-8 1 ea0228381-s8_180lifesci.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on January 27, 2025

    Registration No. 333-                

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    180 LIFE SCIENCES CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   90-1890354
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    3000 El Camino Real, Bldg. 4, Suite 200

    Palo Alto, California

      94306
    (Address of principal executive offices)   (Zip Code)

     

    THIRD AMENDED AND RESTATED

    180 LIFE SCIENCES CORP.

    2022 OMNIBUS INCENTIVE PLAN

    (Full title of the plan)

     

    Blair Jordan

    Interim Chief Executive Officer

    180 Life Sciences Corp.

    3000 El Camino Real, Bldg. 4, Suite 200

    Palo Alto, CA 94306

    (Name and address of agent for service)

     

    (650) 507-0669

    (Telephone number, including area code, of agent for service)

     

    Copy to:

    David M. Loev, Esq.

    John S. Gillies, Esq.

    The Loev Law Firm, PC

    6300 West Loop South, Suite 280

    Bellaire, Texas 77401

    Telephone: (713) 524-4110

    Facsimile: (713) 524-4122

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

     

    Pursuant to General Instruction E of Form S-8, 180 Life Sciences Corp. (“Registrant”) is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) to register 776,321 additional shares of the Registrant’s common stock, $0.0001 par value per share, for issuance under the Registrant’s 2022 Omnibus Incentive Plan (the “Plan”), pursuant to an amendment to the Plan increasing the number of shares reserved for issuance thereunder by 776,321, effective as of December 27, 2024. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on August 9, 2022 (Registration No. 333-266716); August 30, 2023 (Registration No. 333-274276); and April 18, 2024 (Registration No. 333-278772). In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

     

     

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed with the Commission by the Company are incorporated by reference into this registration statement on Form S-8 (the “Registration Statement”) and are made a part hereof:

     

    (a)The Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 25, 2024, as amended by Amendment No. 1 thereto filed with the SEC on April 29, 2024 (File No. 001-38105) (as amended, the “Annual Report”);

     

    (b)The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 15, 2024 (File No. 001-38105), the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024 (File No. 001-38105) and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 14, 2024 (File No. 001-38105);

     

    (c)The Company’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on November 12, 2024, to the extent filed and not furnished with the Commission;
       
     (c) The Company’s Current Reports on Form 8-K and 8-K/A (other than information furnished rather than filed) filed with the SEC on January 16, 2024, January 17, 2024, January 29, 2024, February 16, 2024, February 20, 2024, February 26, 2024, February 28, 2024, February 29, 2024, March 1, 2024, March 8, 2024, March 11, 2024, March 14, 2024, April 19, 2024, May 9, 2024, May 15, 2024, May 21, 2024, July 2, 2024, July 23, 2024, July 30, 2024, September 9, 2024, September 12, 2024, October 3, 2024, October 9, 2024, October 16, 2024, October 16, 2024, October 21, 2024, October 29, 2024, October 29, 2024, December 4, 2024, December 12, 2024, December 18, 2024, December 30, 2024 and January 2, 2024 (File No. 001-38105);

     

      (d) The description of the Company’s Common Stock contained in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, as Exhibit 4.6 (File No. 001-38105), including any amendment or report filed for the purpose of updating such description; and

     

      (e) All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since the end of the fiscal year covered by the Annual Report referred to in (a) above.

     

    All reports and documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports and documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-1

     

     

    Item 5. Interests of Named Experts and Counsel

     

    None.

     

    Item 8. Exhibits

     

    Reference is made to the attached Exhibit Index, which is incorporated herein by reference.

     

    Item 9. Undertakings

     

      (a) The Company hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the Form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    However, paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, our company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of North Vancouver, British Columbia, Canada, on the January 27, 2025.

     

      180 LIFE SCIENCES CORP.
       
      By: /s/ Blair Jordan 
      Name:  Blair Jordan
      Title: Interim Chief Executive Officer
    (Principal Executive Officer and Principal Financial/Accounting Officer)

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that the persons whose signature appears below constitute and appoint Blair Jordan, as such person’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement, and any and all amendments thereto (including post-effective amendments), and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing necessary or desirable to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Blair Jordan   Interim Chief Executive Officer and Director   January 27, 2025
    Blair Jordan   (Principal Executive Officer and Principal Financial/Accounting Officer)    
             
    /s/ Lawrence Steinman   Director   January 27, 2025
    Lawrence Steinman        
             
    /s/ Stephen Shoemaker   Director   January 27, 2025
    Stephen Shoemaker        
             
    /s/ Jay Goodman   Director   January 27, 2025
    Jay Goodman        
             
    /s/ Ryan L. Smith   Director   January 27, 2025
    Ryan L. Smith        
             

     

    II-3

     

     

    EXHIBIT INDEX

     

            Incorporated by Reference   Filed
    Exhibit No.   Description   Form   File No.   Exhibit   Filing Date   Herewith
    4.1   Second Amended and Restated Certificate of Incorporation   8-K   001-38105   3.1   11/12/2020    
    4.2   Certificate of Amendment of Second Amended and Restated Certificate of Incorporation, filed with the Secretary of State of Delaware on December 15, 2022   8-K   001-38105   3.1   12/16/2022    
    4.3   Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of 180 Life Sciences Corp., filed with the Secretary of State of Delaware on February 26, 2024   8-K   001-38105   3.1   2/28/2024    
    4.4   Certificate of Designations of 180 Life Sciences Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock    8-K   001-38105   3.1   10/3/2024    
    4.5   Second Amended and Restated Bylaws of 180 Life Sciences Corp., effective as of September 4, 2023   8-K   001-38105   3.1   09/07/2023    
    5.1*   Opinion of The Loev Law Firm, PC                    
    23.1*   Consent of Marcum LLP                   X
    23.2*   Consent of The Loev Law Firm, PC (included in Exhibit 5.1)                   X
    24.1*   Power of Attorney (included on the signature page of this registration statement)                   X
    99.1   Third Amendment to 180 Life Sciences Corp. 2022 Omnibus Incentive Plan***   8-K   001-38105   10.1   12/31/2024    
    99.2   Third Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan***   8-K   001-38105   10.2   12/31/2024    
    99.3   Form of Stock Option Agreement (2022 Omnibus Incentive Plan) ***   S-8   333-266716   4.2   08/09/2022    
    99.4   Form of Restricted Stock Grant Agreement (2022 Omnibus Incentive Plan) ***   S-8   333-266716   4.3   08/09/2022    
    107*   Filing Fee Table                   X

     

    * Filed herewith.
    *** Indicates management contract or compensatory plan or arrangement.

     

    II-4

     

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF

    DatePrice TargetRatingAnalyst
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla Unveils New Brand Committed to Advancing Ethereum Treasury Strategy

    Company announces new ticker (formally ATNF) and will begin trading on NASDAQ under ETHZ on August 18, 2025 Company has accumulated 94,675 ETH at an average acquisition price of $3,902.20, which is now valued at approximately $419 million PALM BEACH, Fla., Aug. 18, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), (the "Company" or "ETHZilla"), today announced the official launch of its new brand as part of the Company's transition to focus on its recently announced Ethereum treasury strategy. Previously operating as 180 Life Sciences Corp., ETHZilla will focus a significant portion of its non-legacy operations on becoming an accumulation vehicle for Ether (ETH) that is built for the

    8/18/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences (ETHZilla) Holds 82,186 ETH

    Company Initiates Institutional ETH Accumulation Strategy PALO ALTO, Calif., Aug. 12, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), dba ETHZilla (the "Company", "180 Life Sciences" or "ETHZilla"), announced today that is has total holdings of 82,186 Ether ("ETH") at an average acquisition price of $3,806.71, which is now valued at approximately $349 million. In addition to the ETH, ETHZilla holds approximately $238 million in USD cash equivalents. "At ETHZilla we have put over $350 million in capital to work since the PIPE transaction we completed last week, and

    8/12/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings This milestone follows the announcement of the Company's recently closed $425 million private placement PALO ALTO, Calif., Aug. 11, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), today announced that it has sold approximately $156 million aggregate principal amount of senior secured convertible notes due 2028 (the "Convertible Notes") in a private offering to an institutional investor on August 8, 2025. The Company intends to us

    8/11/25 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    SEC Filings

    View All

    SEC Form PRE 14A filed by 180 Life Sciences Corp.

    PRE 14A - ETHZilla Corp (0001690080) (Filer)

    8/26/25 5:20:58 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    8/25/25 8:00:36 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ETHZilla Corp (0001690080) (Filer)

    8/22/25 7:12:17 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Jordan Blair disposed of 200,000 shares (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    8/25/25 6:53:40 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Former 10% Owner Elray Resources, Inc. sold $9,278,586 worth of shares (2,998,000 units at $3.09) and exercised 3,000,000 in-the-money shares at a strike of $1.68, increasing direct ownership by 0.15% to 1,320,000 units (SEC Form 4)

    4 - ETHZilla Corp (0001690080) (Issuer)

    8/18/25 5:27:22 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Rudisill Mcandrew

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    8/12/25 5:20:03 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

    Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

    9/15/21 7:48:59 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

    4 - 180 Life Sciences Corp. (0001690080) (Issuer)

    12/18/23 4:15:16 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Financials

    Live finance-specific insights

    View All

    180 Life Sciences Corp. - Corporate Updates

    Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

    10/3/24 8:30:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    10/18/24 5:00:02 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 180 Life Sciences Corp.

    SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

    2/14/24 3:27:19 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    Leadership Updates

    Live Leadership Updates

    View All

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

    PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

    12/12/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

    PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

    12/4/24 8:00:00 AM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care